ETIDRONATE TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

ETIDRONATE DISODIUM

থেকে পাওয়া:

COBALT PHARMACEUTICALS COMPANY

এটিসি কোড:

M05BA01

INN (আন্তর্জাতিক নাম):

ETIDRONIC ACID

ডোজ:

200MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

ETIDRONATE DISODIUM 200MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

14/100/500

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

BONE RESORPTION INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0113205002; AHFS:

অনুমোদন অবস্থা:

CANCELLED PRE MARKET

অনুমোদন তারিখ:

2017-09-01

পণ্য বৈশিষ্ট্য

_ _
_ _
_Page 1 of 30_
PRODUCT MONOGRAPH
Pr
ETIDRONATE
Etidronate Disodium
Tablets(s) 200 mg and 400 mg
USP
Bone Metabolism Regulator, Anti-Pagetic Agent,
Anti-Hypercalcemic Agent
Manufactured by:
Cobalt Pharmaceuticals Inc.
6500 Kitimat Road
Mississauga, Ontario
L5N 2B8
Date of Preparation:
March 26, 2010
Control No. : 137100
_ _
_ _
_Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS....................................................................................................9
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND
ADMINISTRATION..............................................................................12
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................15
STORAGE AND
STABILITY..........................................................................................16
SPECIAL HANDLING INSTRUCTIONS
.......................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................17
PART II: SCIENTIFIC INFORMATION
...............................................................................18
PHARMACEUTICAL
INFORMATION..........................................................................18
CLINICAL
TRIALS.......................................